Next Article in Journal
Porphyra tenera Protects against PM2.5-Induced Cognitive Dysfunction with the Regulation of Gut Function
Next Article in Special Issue
Total Syntheses of the Proposed Structure of Iriomoteolide-1a, -1b and Synthesis of Three Derivatives for Structural Studies
Previous Article in Journal
Preparation and Characterization of Tilapia Collagen-Thermoplastic Polyurethane Composite Nanofiber Membranes
Previous Article in Special Issue
Isolation and Structure Elucidation of New Cytotoxic Macrolides Halosmysins B and C from the Fungus Halosphaeriaceae sp. Associated with a Marine Alga
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 20
Issue 7
10.3390/md20070438
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of 6-Halo-Substituted Pericosine A and an Evaluation of Their Antitumor and Antiglycosidase Activities

by
Yoshihide Usami
1,*,
Yoshino Mizobuchi
1,
Mai Ijuin
1,
Takeshi Yamada
2,
Mizuki Morita
1,
Koji Mizuki
1,
Hiroki Yoneyama
1 and
Shinya Harusawa
1
1
Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan
2
Department of Medicinal Molecular Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan
*
Author to whom correspondence should be addressed.
Mar. Drugs 2022, 20(7), 438; https://doi.org/10.3390/md20070438
Submission received: 17 June 2022 / Revised: 25 June 2022 / Accepted: 28 June 2022 / Published: 30 June 2022
(This article belongs to the Special Issue Chemical Modification and Structural Elucidation of Marine Natural Products)
Browse Figures
Review Reports Versions Notes

Abstract

:
The enantiomers of 6-fluoro-, 6-bromo-, and 6-iodopericosine A were synthesized. An efficient synthesis of both enantiomers of pericoxide via 6-bromopericosine A was also developed. These 6-halo-substituted pericosine A derivatives were evaluated in terms of their antitumor activity against three types of tumor cells (p388, L1210, and HL-60) and glycosidase inhibitory activity. The bromo- and iodo-congeners exhibited moderate antitumor activity similar to pericosine A against the three types of tumor cell lines studied. The fluorinated compound was less active than the others, including pericosine A. In the antitumor assay, no significant difference in potency between the enantiomers was observed for any of the halogenated compounds. Meanwhile, the (−)-6-fluoro- and (−)-6-bromo-congeners inhibited α-glucosidase to a greater extent than those of their corresponding (+)-enantiomers, whereas (+)-iodopericosine A showed increased activity when compared to its (−)-enantiomer.

Graphical Abstract

1. Introduction

Chemical modification of bioactive natural products is one of the most common methods used in drug development [1,2,3,4,5,6,7,8]. In addition to increasing the pharmacological activity, which is the major aim of chemical modification, decreasing side effects, improving the solubility or stability, and reducing costs remain problems to be resolved during drug development. Chemical modification based on marine natural products has been extensively studied due to the discovery of new lead compounds suitable for drug discovery [9,10,11,12].
The isolation of pericosine A (1Cl) and B (2) as metabolites of the marine-derived fungus Periconis byssoides N133 was first reported in 1997, and pericosines C–E (3–6) were discovered in 2008 [13,14,15]. The unique carbasugar structures constituting the highly functionalized cyclohexene ring are shown in Figure 1. Recently, the chemistry of carbasugars has received an increasing amount of research attention due to their wide range of biological activity [16,17,18]. In addition, many total syntheses of pericosines A–C (1–3) have been reported due to the antitumor activity of pericosine A (1Cl) [19,20,21,22,23,24,25,26,27,28,29,30]. However, the chemical modification of the pericosines has not been reported to date with the exception of our synthetic study on pericosine E analogs bearing chloro- or methoxy-substituents at C-6, which were used as α-glucosidase inhibitors [31,32]. Figure 1 also includes (+)-pericoxide (7) and (−)-maximiscin, which were discovered by Cichewitcz and coworkers from Tolypocladium sp. [33,34]. The fact that pericosine 1Cl was obtained together with pericoxide 7 in their work suggests that 7 may be a biosynthetic precursor of 1Cl. Therefore, 7 should be classified as a member of the pericosine family.
In our recent report on pericosine A, natural 1Cl was isolated from Periconia sp. as an enantiomeric mixture. In addition, we confirmed that both synthesized enantiomers of 1Cl exhibit antitumor activity with similar potency against three tumor cell lines (P388, LH-6, and L1210). Furthermore, (−)-1Cl showed moderate α-glucosidase inhibitory activity (IC50 = 2.25 mM), whereas (+)-1Cl was inactive [35]. As we are interested in the biological activities of pericosine congeners bearing other halogen atoms, the fermentation of Periconia sp in artificial seawater containing fluoride, bromide, or iodide sources has been examined as an alternative to chloride. It should be mentioned here that 6-halogenated pericosines bearing F, Br, or I atoms were not obtained in our preceding paper. Consequently, we have attempted the synthesis of non-natural 6-halo-substituted pericosine A. Our recent synthetic work on pericosine E analogs has suggested that the presence of a chlorine atom at C6 is an important factor for α-glucosidase inhibitory activity. The preparation of other 6-halo-congeners is also required for our continuous synthetic studies on new pericosine E analogs.
Herein, we describe the synthesis and evaluation of the antitumor and antiglycosidase inhibitory activities of both enantiomers of newly designed 6-halo-congeners of pericosine A. In addition, an efficient synthesis of closely related pericoxide 7 via 6-bromo pericosine A (1Br) has also been reported.

2. Results & Discussion

2.1. Synthesis of Both Enantiomers of 6-Halo-Substituted Pericosine A

A similar reaction to the hydrochlorination of epoxide intermediate 8 used in the synthesis of pericosine A 1Cl [21,29] using commercially available HBr and HI aqueous solutions was envisioned in this study, in which the deprotection of the hydroxyl groups and hydrolysis of the ester moiety will occur (Scheme 1). Subsequently, we began this work by searching for suitable reagents used to introduce the required fluorine, bromine, or iodine atoms.
For bromination, BBr3 was initially examined as the bromide source to react with epoxide (−)-8, which can be prepared from bromohydrin (+)-9 via an intramolecular SN2 reaction [29,31]. However, careful addition of BBr3 [0.33 equivalents (eq)] to (−)-8 in dry diethyl ether (Et2O) at −78 °C afforded the desired product (10Br) in only 14% yield. Using 1.0 eq of BBr3 slightly improved the yield (38%), but increasing the reaction temperature led to the formation of a complicated mixture including the undesired regioisomer. After investigating a variety of brominating reagents, we found mono-bromoborane dimethyl sulfide complex (BH2Br·SMe2) to be the most suitable for the desired reaction [36,37]. The reaction of 8 with 1.0 eq of BH2Br·SMe2 at −78 °C in Et2O dramatically improved the yield of (−)-10Br to 94% yield. The reactions performed at higher temperatures led to a decreased yield of (−)-10Br (78% at −20 °C and 58% at 0 °C). Subsequent deprotection of the cyclohexylidene moiety was also a delicate process. The optimum reaction conditions were found after investigating a variety of conditions. Treatment of (−)-10Br with Dowex® 50WX8 hydrogen form (Dowex® 50WX8-H: Acidic ion-exchange resin) in MeOH at room temperature (rt) for 56 h gave (−)-1Br in an excellent 87% yield when compared to the conventional reaction using trifluoroacetic acid (TFA) in MeOH (66%) (Scheme 1A). This deprotection process with Dowex-XW50-H was examined in detail because could also be applied in the subsequent synthesis of pericoxide 7 (see Supplementary Material, Table S1).
The corresponding (+)-enantiomer of 1Br was prepared in the same way using (+)-8 derived from (−)-quinic acid (Scheme 1B). Iodohydrination of (−)-8 was then achieved upon careful addition of 0.33 eq of aluminum iodide (AlI3) at 0 °C to give the desired product [(−)-10I] in 63% yield [38]. When 1.0 eq of AlI3 was used under the same reaction conditions, the yield of (−)-10I was reduced to 15%. The reaction of (−)-8 with 1.0 eq of tetrabutylammonium iodide and a catalytic amount of BF3·Et2O in dry dichloromethane at −78 °C afforded (−)-10I in 17% yield. Finally, deprotection of (−)-10I was achieved under conventional TFA/MeOH conditions to give (−)-1I in 76% yield, whereas treatment of (−)-10I with Dowex® 50WX8-H resulted in no reaction. The (+)-enantiomer of 1I was prepared using a similar approach from (+)-8 via (+)-10I.
The introduction of a fluorine atom into (−)-8 was accomplished using the (HF)n/py complex. The reaction of (−)-8 with this complex at 0 °C for 15 min in a polypropylene tube afforded the desired fluorohydrine product [(−)-10F] in 46% yield. A longer reaction time (1 h) led to a more complex product mixture, giving a low yield of (−)-10F (32%). Subsequent treatment of (−)-10F with TFA in MeOH afforded (−)-1F in 43% yield. Similarly, (+)-1F was successfully obtained using (+)-8. It should be noted that 10I and 1I are relatively unstable when compared to the other halogenated congeners, so they were stored in a freezer prior to further use.

2.2. Synthesis of Pericoxide

The synthesis of 7, which was not reported prior to 2019, was also conducted, as shown in Scheme 2. The direct deprotection of epoxide 8 was examined in our preliminary efforts to prepare 7. Treatment of (−)-8 with trifluoroacetic acid in t-BuOH at room temperature (rt) did not afford pericoxide 7 despite the complete consumption of 8. Changing the acid catalyst to Dowex® 50WX8-H resulted in no reaction and microwave (MW) heating afforded a small amount of methyl 3,4-dihydroxybenzoate along with the recovery of the starting material [(−)-8].
In our next experiment, bromotriol 11 derived from bromohydrin 9 was treated with 3.0 eq of lithium hexamethyldisilazide (LHMDS) in THF at −78 °C because if the C6 hydroxide anion attacked the C5 center faster than the C4 hydroxide anion, the formation of 7 via an intramolecular SN2 process was expected to occur. However, the spectral data of epoxide 12 did not agree with those of 7. The structure of 12 was determined using NMR spectroscopy; epoxy carbon atoms C6 (δ 55.5 ppm) and C1 (δ 56.0 ppm) were detected in the high field region in the 13C-NMR spectrum and the HMBC cross peaks corresponding to H1/C3 and H6/C4 indicated the structure of 12 (see Supplementary Materials).
Finally, (−)-bromopericosine A (1Br) was treated with 3.0 eq of LHMDS at −78 °C to give (−)-7, which is an enantiomer of the natural product. The isolated yield of (−)-7 upon purification via conventional acidic silica gel column chromatography was only 23%, but this was improved to 77% using neutral silica gel. The spectral data agree with those of natural pericoxide with the exception of the sign of its specific rotation. Unfortunately, (−)-7 was so unstable that it decomposed upon storage at rt in methanol, exhibiting a smaller optical rotation within a couple of days. Furthermore, the decomposed residue exhibits a positive specific rotation, although freshly synthesized 7 was negative. Regrettably, biological assays of 7 could not be performed because of this inherent instability.
Treatment of 1Br with 2.0 eq of LHMDS led to a decreased yield of 7 (57%) along with the recovered starting material (1Br; 34%). Alternatively, intramolecular epoxidation of (−)-1Cl with LHMDS (3.0 eq) gave (−)-7 in 12% yield along with the recovery of (−)-1Cl (20%).
This experiment indicates the significance of bromo-derivative 1Br as the starting material. Using the same synthetic process, natural (+)-7 was synthesized via (+)-1Br starting from (−)-quinic acid. A similar synthesis of (+)-7 from (+)-1Cl has been previously reported by Cichewitz in 2019 [39].

2.3. Evaluation of the Biological Activities of Enantiomerically Pure Pericosine A and Its 6-Halogenated Congeners

2.3.1. Antitumor Assay

The antitumor activity of halo-compounds 1 was evaluated against three types of tumor cell lines: Basic P388 (mouse lymphocytic leukemia), L1210 (mouse lymphocytic leukemia), and LH60 (human promyelocytic leukemia) cell lines, along with a previously reported procedure using 5-fluorouracil (5-FU) as a positive control [35]. The results are presented in Table 1, including those obtained for perocosine A (1Cl), which has been previously reported in the literature, for comparison. All compounds showed antitumor activity against the three types of tumor cell lines studied. Bromo- and iodo-pericosine (1Br and 1I) show similar activities to 1Cl, but fluorinated compound 1F was less active than all of the other compounds, including 1Cl. Because pericosine C (3), which exists as an enantiomeric mixture in nature and has the same relative configuration to 1s, was reported to be inactive against P-388 cell line [14], present results implied the importance of the presence of halogen atom at C-6 in pericosine core structure for antitumor activity. In addition, it is noteworthy that no significant difference in the potency was observed between the enantiomers, similar to pericosine A.

2.3.2. Glycosidase Inhibitory Activity Assay

There have been several excellent studies on the development of pseudosugar-type glycosidase inhibitors [40,41,42,43,44,45,46,47,48,49,50]. The compounds synthesized in this study were also applied to an glycosidase inhibitory assay against five kinds of enzymes: α-Glucosidase from yeast, β-glucosidase from Jack bean, α-galactosidase from green coffee bean, β-galactosidase from bovine liver, and α-mannosidase from bovine liver. The results are presented in Table 2 along with the previous results obtained for pericosine A (1Cl) for comparison [35]. (−)-1F, (−)-1Br, and (−)-1I exhibit comparable inhibitory activities to (−)-1Cl (IC50 = 2.25 mM) against α-glucosidase with IC50 values of 1.95, 1.79, and 3.60 mM, respectively, whereas they were less active than the positive control [deoxynojirimycin (DNJ); IC50 = 0.0965 mM]. (+)-1Br showed less potent activity (IC50 = 5.05 mM) when compared to (−)-1Br, and (+)-1F was inactive similar to (+)-1Cl. Surprisingly, (+)-1I exhibited the most potent α-glucosidase inhibitory activity (IC50 = 1.15 mM) among the eight compounds studied and was active against α-galactosidase (IC50 = 3.56 mM). This is the only example of an α−galactosidase inhibitor among the pericosines and their congeners reported to date.
All of the synthesized compounds were inactive against β-glucosidase and α-galactosidase. Interestingly, (−)-1Br showed dual activity against β-galactosidase and α-glucosidase similar to (−)-1Cl, but they were less active than those reported for some pericosine E derivatives [33].

3. Materials and Methods

General methods: HRMS was performed on a JMS-700 (2) mass spectrometer (JEOL, Tokyo, Japan). NMR spectra were recorded at 27 °C on 300- and 400-MR-DD2, INOVA-500 and 600-DD2 spectrometers (Agilent Technologies, CA, USA) in CDCl3 or acetone-d6 using tetramethylsilane (TMS) as an internal standard. Specific rotations were measured using a DIP1000 digital polarimeter (JASCO Co., Tokyo, Japan). Liquid column chromatography was conducted on silica gel (BW-127ZH) (Fuji Silysia, Tokyo, Japan) or neutral silica gel (CHROMATOREX DIOL MB100–75/200) (Fuji Silysia, Tokyo, Japan). Analytical TLC was performed on precoated silica gel 60 plates (Merck & Co., Inc., Darmstadt, Germany) and the compounds were viewed by dipping the plates in an ethanol solution of phosphomolybdic acid, followed by heating. Microwave-aided reactions were performed using Initiator® (Biotage, Uppsala, Sweden). Flash chromatography was performed using Isolera One® (Biotage, Uppsala, Sweden). (−)-Shikimic acid was purchased from Carbosynth Ltd. (UK). (−)-Quinic acid was purchased from Merck & Co., Inc. (Darmstadt, Germany). AlI3, HCl, BH2Br, SMe2, and Dowex® 50WX8-H were purchased from Sigma-Aldrich (St. Louis, MO). n-BuLi in hexane was purchased from Nacalai Tesque (Kyoto, Japan). Hexamethyldisilazane and (HF)n/py complex were purchased from TCI (Tokyo, Japan). Trifluoroacetic acid, dry MeOH, CH2Cl2, Et2O, and tetrahydrofuran (THF) were purchased from Wako Pure Chemical Industries (Osaka, Japan).

3.1. Synthesis of Both Enantiomers of The 6-Halopericosine A Analogs

3.1.1. Synthesis of Methyl (−)-3,4-O-Cyclohexylidene-6-Fluoro-3,4,5-Trihydroxy-1-CycloHexene Carboxylate (10F)

To a solution of (−)-8 (13.4 mg, 0.050 mmol) in CH2Cl2 (1.0 mL) in a polyethylene tube and cooled at 0 °C was added 12.5 mL of (HF)n/pyridine complex (67% w/v HF, 4.0 mmol). The resulting mixture was stirred at 0 °C for 15 min and quenched upon adding saturated (sat.) NaHCO3 (aq) (10 mL). The mixture was then extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated to afford the crude product, which was purified by column chromatography on neutral silica gel (eluent = Hexane:EtOAc = 9:1) to afford (−)-10F as a colorless oil (6.6 mg, 46%). [α]D20 −41.1 (c 0.12, CHCl3); 1H-NMR (CDCl3, 500 MHz) δ 1.22–1.71 (10H, m), 2.51 (1H, dd, J = 4.1 1.6 Hz, 5-OH), 3.83 (3H, s, -COOCH3), 4.20 (1H, dddd, J = 10.3, 5.5, 4.5, 3.2 Hz, H-5), 4.56 (1H, ddd, J = 6.2, 3.2, 3.0 Hz, H-4), 4.76 (1H, dddd, J = 6.2, 5.5, 3.2, 0.9 Hz, H-3), 5.56 (1H, dd, J = 48.0, 5.5 Hz, H-6), 7.01 (1H, br dd, J = 3.2, 2.8 Hz, H-2); 13C-NMR (CDCl3, 125 MHz) δ 23.6 (CH2), 23.9 (CH2), 24.9 (CH2), 34.5 (CH2), 36.6 (CH2), 52.4 (CH3, CO2CH3), 67.6 (d, 2JC-F = 24.9 Hz, CH, C-5), 70.9 (d, 4JC-F = 2.4 Hz, CH, C-3), 73.4 (d, 3JC-F = 5.8 Hz, CH, C-4), 86.2 (d, 1JC-F = 168.8 Hz, CH, C-6), 111.2, 128.6 (d, 2JC-F = 17.7 Hz, CH, C-1), 139.4 (d, 3JC-F = 5.8 Hz, CH, C-2), 165.2 (Cq, COOMe); HREIMS m/z calcd for C14H19O5F [M]+ 286.1217, found 286.1218.
(+)-10F (7.1 mg, 43%) was synthesized from (+)-8 (15.5 mg, 0.058 mmol) in the same manner as (−)-10F. [α]D20 +37.6 (c 0.13, CHCl3); 1H-NMR (CDCl3, 400 MHz) δ 1.22–1.70 (10H, m), 2.51 (1H, d, J = 3.0 Hz, 5-OH), 3.83 (3H, s, -COOCH3), 4.17–4.24 (1H, m, H-5), 4.56 (1H, dt, J = 6.3, 3.1 Hz, H-4), 4.76 (1H, ddd, J = 6.0, 5.5, 3.1 Hz, H-3), 5.56 (1H, dd, J = 48.1, 5.5 Hz, H-6), 7.01 (1H, br dd, J = 2.8, 2.5 Hz, H-2); 13C-NMR (CDCl3, 100 MHz) δ 23.6, 23.9, 24.9, 34.5, 36.6, 52.4, 67.6 (d, 2JC-F = 25.2 Hz, C-5), 70.9 (d, 4JC-F = 2.3 Hz, C-3), 73.4 (d, 3JC-F = 5.4 Hz, C-4), 86.2 (d, 1JC-F = 168.6 Hz, C-6), 111.2 (Cq), 128.5 (d, 2JC-F = 17.6 Hz, CH, C-1), 139.4 (d, 3JC-F = 5.3 Hz, C-2), 165.2 (Cq, COOMe); HREIMS m/z calcd for C14H19O5F [M]+ 286.1217, found 286.1215.

3.1.2. Synthesis of (−)-6-Fluoropericosine A (1F)

To a solution of (−)-10F (7.5 mg, 0.026 mmol) in MeOH (1.0 mL) was added TFA (2.0 mL) at 0 °C with stirring. The reaction mixture was stirred for another 3.5 h at rt, then condensed under reduced pressure give the crude product, which was purified by column chromatography on neutral silica gel (eluent = 5% MeOH in CH2Cl2) to afford (−)-1F as a colorless oil. [α]D20 −78.7 (c 1.4, MeOH); 1H-NMR (MeOH-d4, 600 MHz, ppm) δ 3.76 (3H, s, -OMe), 3.97 (1H, ddd, J = 16.7, 6.1, 2.0 Hz, H-5), 4.03–4.06 (1H, m, H-4), 4.41–4.44 (1H, m, H-3), 5.42 (1H, dddd, J = 49.6, 6.7, 1.7, 0.6 Hz, H-6), 6.81–6.82 (1H, m, H-2); 13C-NMR (MeOH-d4, 150 MHz, ppm) δ 52.3 (CH3, COOMe), 68.2 (CH, C3, 4JC-F = 2.3 Hz), 72.7 (CH, C4, 3JC-F = 6.9 Hz), 73.3 (CH, C5, 2JC-F = 20.9 Hz), 90.7 (CH, C-6, d, 1JC-F = 167.6 Hz), 129.1 (Cq, C1, d, 2JC-F = 18.5 Hz), 144.4 (CH, C-2, d, 3JC-F = 5.8 Hz), 166.3 (Cq, COOMe); HREIMS m/z calcd for C8H12O5F [M]+ 207.0669, found 207.0668.
(+)-1F (3.5 mg, 59%) was synthesized from (+)-10F (8.2 mg, 0.029 mmol) in the same manner as (−)-1F. Colorless oil; [α]D20 +67.7 (c 0.95, MeOH); H-NMR (MeOH-d4, 600 MHz, ppm) δ 3.73 (3H, s, -OMe), 3.92 (1H, ddd, J = 17.0, 6.1, 2.0 Hz, H-5), 4.03–4.05 (1H, m, H-4), 4.40–4.43 (1H, m, H-3), 5.34 (1H, dddd, J = 49.9, 6.5, 2.1, 0.6 Hz, H-6), 6.75–6.77 (1H, m, H-2); 13C-NMR (MeOH-d4, 150 MHz, ppm) δ 52.4 (CH3, COOMe), 68.3 (CH, C3), 73.0 (CH, C4, 3JC-F = 6.9 Hz), 73.1 (CH, C5, 2JC-F = 20.8 Hz), 90.8 (CH, C-6, d, 1JC-F = 167.6 Hz), 129.0 (Cq, C1, d, 2JC-F = 18.5 Hz), 144.4 (CH, C-2, d, 3JC-F = 6.9 Hz), 166.5 (Cq, COOMe); HREIMS m/z calcd for C8H12O5F [M]+ 207.0669, found 207.0675.

3.1.3. Synthesis of Methyl (−)-6-Bromo-3,4-O-Cyclohexylidene-3,4,5-Trihydroxy-1-CycloHexene Carboxylate (10Br)

To a solution of syn-epoxide (−)-8 (112.8 mg, 0.42 mmol) in Et2O (5 mL) was added a solution 1.0 M BH2Br·SMe2 in CH2Cl2 (0.48 mL, 0.42 mmol) at −78 °C. After stirring at −78 °C for 5 h, the reaction mixture was quenched with saturated NH4Cl aq., and extracted with CH2Cl2 (10 mL × 3). The combined organic layers were dried over MgSO4, filtered, and evaporated to give the crude product, which was almost pure, but purified via silica gel column chromatography (eluent; EtOAc:Hexane = 1:3) to afford (−)-10Br (139.7 mg, 94%). [α]D20 −207.4 (c 0.30, CHCl3); IR (KBr) νmax 3471 (OH), 1724 (C=O), 1652 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 1.37–1.71 (10H, m, 5 × CH2), 3.80 (3H, s, -OMe), 4.17 (1H, d, J = 4.1 Hz, OH), 4.29 (1H, ddd, J = 4.4, 4.1, 3.5 Hz, H-5), 4.71 (1H, br dd, J = 7.0, 3.5 Hz, H-4), 4.88 (1H, br dd, J = 7.0, 3.2 Hz, H-3), 4.99 (1H, br d, J = 4.4 Hz, H-6), 6.99 (1H, dd, J = 3.2, 1.5 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 24.4 (CH2), 24.7 (CH2), 25.8 (CH2), 34.91 (CH2), 34.93(CH2), 36.8 (CH2), 44.0 (CH, C-6), 52.6 (Cq, -OCH3), 68.9 (CH. C-5), 70.8 (CH, C-3), 73.6 (CH, C-4), 111.1 (Cq), 131.6 (Cq, C-1), 138.6 (CH, C-2), 165.8 (Cq, COOMe); 1H-NMR (CDCl3, 600 MHz, ppm) δ 1.40–1.73 (10H, m, 5 × CH2), 2.70 (1H, d, J = 2.3 Hz, OH), 3.83 (3H, s, -OMe), 4.35–4.37 (1H, m, H-5), 4.75–4.79 (2H, m, overlapped, H-3,4), 4.88 (1H, br dd, J = 7.0, 3.2 Hz, H-3), 5.09 (1H, d, J = 3.8 Hz, H-6), 7.17 (1H, dd, J = 1.8, 1.1 Hz, H-2); 13C-NMR (CDCl3, 150 MHz, ppm) δ 23.5 (CH2), 23.9 (CH2), 25.1 (CH2), 33.3 (CH2), 36.0 (CH2), 40.4 (CH-C6), 52.5 (Cq, -OCH3), 67.0 (CH, C-5), 69.4 (CH, C-3), 71.6 (CH, C-4), 110.7 (Cq), 130.7 (Cq, C-1), 137.4 (CH, C-2), 164.7 (Cq, COOMe): C14H19O581Br [M]+ 348.0395 found 348.0395. HREIMS m/z calcd for C14H19O579Br [M]+ 346.0416 found 346.0415, C14H19O581Br1 (M)+ 348.0395 found 348.0395.
(+)-10Br (57.6 mg, 83%) was synthesized from (+)-8 (53.2 mg, 0.20 mmol) in the same manner as (−)-10Br. Colorless crystals (CH2Cl2); mp 117–120 °C; [α]D20 +204.0 (c 0.29, CHCl3); 1H-NMR (acetone-d6, 600 MHz, ppm) δ 1.38–1.72 (10H, m, 5 × CH2), 3.81 (3H, s, OMe), 4.19 (1H, d, J = 4.1 Hz, 5-OH), 4.27–4.30(1H, m, H-5), 4.71 (1H, br dd, J = 7.0, 3.5 Hz, H-4), 4.88 (1H, dd, J = 7.0, 2.9 Hz, H-3), 4.99 (1H, d, J = 4.4 Hz, H-6), 6.99 (1H, dd, J = 3.3, 1.5 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 24.4 (CH2), 24.7 (CH2), 25.8 (CH2), 34.9 (CH2), 36.8 (CH2), 44.0 (CH, C-6), 52.6 (CH3, COOMe), 68.9 (CH, C5), 70.8 (CH, C3), 73.6 (CH, C4), 111.1 (Cq), 131.6 (Cq, C1), 138.7 (CH, C-2), 165.8 (Cq, COOMe); HREIMS m/z calcd for C14H19O579Br [M]+ 346.0416, found 346.0415, C14H19O581Br [M]+ 348.0395, found 348.0395.

3.1.4. Synthesis of (−)-6-Bromopericosine A (1Br)

Table S1, entry 4: To a solution of (−)-10Br (41.3 mg, 0.12 mmol) in MeOH (2.0 mL) was added Dowex® 50WX8-H (102.5 mg) and the resulting mixture was stirred for 56 h at room temperature. The reaction mixture was filtered and the filtrate concentrated under reduced pressure to give a crude residue, which was purified with silica gel column chromatography (eluent; CH2Cl2:MeOH = 95: 5) to afford (−)-1Br (27.6 mg, 87%) and recovered (−)-10Br (5.5 mg, 13%). (−)-1Br: Amorphous solid; mp 96–99 °C; [α]D20 −130.8 (c 1.38, MeOH); IR (film) νmax 3219 (OH), 1712 (C=O) cm−1; 1H-NMR (CD3OD, 600 MHz, ppm) δ 3.80 (3H, s, COOMe), 4.10 (1H, dd, J = 4.4, 2.1 Hz, H-4), 4.18 (1H, ddd, J = 4.4, 2.0 Hz, H-5), 4.36 (1H, br dd, J = 4.4, 4.1Hz, H-3), 4.94 (1H, dd, J = 4.4, 0.9 Hz, H-6), 6.86 (1H, d, J = 4.1 Hz, H-2); 13C-NMR (CD3OD, 150 MHz, ppm) δ 48.7 (CH, C-6), 52.8 (CH3, COOMe), 67.6 (CH, C-3), 69.3 (CH, C-4), 76.2 (CH, C-5), 131.8 (Cq, C-1), 141.6 (CH, C-2), 167.3 (Cq, COOMe); HREIMS m/z calcd for C8H12O579Br [M + H]+ 266.9868 found 266.9869.
(+)-1Br (37.7 mg, 78%) was synthesized from (+)-10Br (57.6 mg, 0.166 mmol) in the same manner as (−)-1Br. Amorphous solid; mp 96–99 °C; [α]D20 +130.2 (c 1.74, MeOH); 1H-NMR (MeOH-d4, 600 MHz, ppm) δ 3.80 (3H, s, -OMe), 4.10 (1H, J = 4.4, 2.1 Hz, H-5), 4.10 (1H, dd, J = 4.4, 2.1 Hz, H-4), 4.36 (1H, br dd, J = 4.7, 4.4 Hz, H-3), 4.94 (1H, dd, J = 4.4, 0.9 Hz, H-6), 6.86 (1H, d, J = 4.1 Hz, H-2); 13C-NMR (MeOH-d4, 150 MHz, ppm) δ 48.6 (CH, C-6), 52.8 (CH3, COOMe), 67.6 (CH, C5), 69.3 (CH, C3), 76.2 (CH, C4), 131.8 (Cq, C1), 141.6 (CH, C-2), 167.3 (Cq, COOMe); HREIMS m/z calcd for C8H10O579Br [M − H]+ 264.9712, found 264.9713.

3.1.5. Synthesis of Methyl (−)-3,4-O-Cyclohexylidene-3,4,5-Trihydroxy-6-iodo-1-CycloHexene Carboxylate (10I)

To a solution of (−)-8 (14.4 mg, 0.056 mmol) in CH2Cl2 (1.0 mL) was added AlI3 (7.9 mg, 0.019 mmol) at 0 °C with stirring. After stirring for 2 h at 0 °C, the reaction was quenched by adding sat. NaHCO3 (aq) (5 mL). The resulting mixture was then extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated to afford the crude product, which was purified by silica gel column chromatography (eluent = Hexane:EtOAc = 5:1) to afford (−)-10I (15.5 mg, 60%) as a white powder. mp 97–99 °C; [α]D20 –261.4 (c 0.09, CHCl3); 1H-NMR (CDCl3, 600 MHz, ppm) δ 1.43–1.74 (10H, m), 2.70 (1H, d, J = 2.3 Hz, 5-OH), 3.82 (3H, s, -OMe), 4.36 (1H, ddd, J = 4.1, 3.2, 2.3 Hz, H-5), 4.74 (1H, dd, J = 7.9, 3.2 Hz, H-3), 4.86 (1H, dd, J = 7.9, 4.1 Hz, H-4), 5.21 (1H, d, J = 3.2 Hz, H-6), 7.10 (1H, d, J = 3.2 Hz, H-2); 13C-NMR (CDCl3, 150 MHz, ppm) δ 16.8 (CH2), 23.5 (CH2), 24.0 (CH2). 25.1 (CH2), 33.3 (CH2), 36.0 (CH, C-6), 52.5 (CH3, COOMe), 68.0 (CH, C-5), 69.1 (CH, C-3), 72.6 (CH, C-4), 110.4 (Cq), 132.5 (Cq, C-1), 135.8 (CH, C-2), 164.7 (Cq, COOMe); HREIMS m/z calcd for C14H10O5I [M]+ 394.0277, found 394.0279.
(+)-10I (17.6 mg, 72%) was synthesized from (+)-8 (16.5 mg, 0.062 mmol) in a similar manner as (−)-10I. White powder; mp 97–100 °C; [α]D20 +262.0 (c 0.13, CHCl3); 1H-NMR (CDCl3, 400 MHz, ppm) δ 1.43–1.74 (10H, m), 2.71 (1H, d, J = 1.6 Hz, 5-OH), 3.82 (3H, s, -OMe), 4.34–4.38 (1H, m, H-5), 4.74 (1H, dd, J = 7.8, 3.1 Hz, H-3), 4.86 (1H, dd, J = 7.8, 3.5 Hz, H-4), 5.21 (1H, d, J = 3.3 Hz, H-6), 7.10 (1H, d, J = 3.2 Hz, H-2); 13C-NMR (CDCl3, 100 MHz, ppm) δ 16.8, 23.5, 23.9. 25.0, 33.2, 35.9, 52.5, 68.0, 69.1, 72.5, 110.4, 132.4, 135.8, 164.6; HREIMS m/z calcd for C14H10O5I [M]+ 394.0277, found 394.0279.

3.1.6. Synthesis of (−)-6-Iodoopericosine A (1I)

To a solution of (−)-10I (4.3 mg, 0.011 mmol) in MeOH (1.0 mL) was added TFA (4.5 mL) at 0 °C with stirring. The reaction mixture was stirred for another 3 h at rt, then concentrated under reduced pressure give a crude residue, which was purified by column chromatography with neutral silica gel (eluent = 5% MeOH in CH2Cl2) to afford (−)-1F as a colorless oil (2.6 mg, 76%). [α]D20 −8.4 (c 0.13, MeOH); 1H-NMR (acetone-d6, 600 MHz, ppm) δ 3.79 (3H, s, -OMe), 4.21 (1H, dd, J = 4.7, 2.1 Hz, H-4), 4.33 (1H, br dd, J = 3.5, 2.1 Hz, H-5), 4.43 (1H, br t, J = 4.7, H-3), 5.16 (1H, dd, J = 3.5, 0.6 Hz, H-6), 6.88 (1H, d, J = 4.4 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 26.8 (CH, C-6), 52.6 (CH3, COOCH3), 66.6 (CH, C5), 67.7 (CH, C-4), 76.9 (CH, C-5), 132.8 (Cq, C1), 139.5 (CH, C-2), 166.4 (Cq, COOMe); HREIMS m/z calcd for C8H11O5I [M]+ 313.9652, found 313.9649.
(+)-1I (1.9 mg, 77%)was synthesized from (+)-10I (3.1 mg, 0.0079 mmol) in a similar manner as (−)-1I; Colorless oil; [α]D20 +11.7 (c 0.10, MeOH); 1H-NMR (acetone-d6, 600 MHz, ppm) δ 3.79 (3H, s, -OMe), 4.21 (1H, dd, J = 4.7, 2.1 Hz, H-4), 4.33 (1H, br dd, J = 3.5, 2.1 Hz, H-5), 4.43 (1H, br t, J = 4.7, H-3), 5.16 (1H, dd, J = 3.5, 0.6 Hz, H-6), 6.88 (1H, d, J = 4.4 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 26.8 (CH, C-6), 52.6 (CH3, COOCH3), 66.7 (CH, C-3), 67.7 (CH, C-4), 76.9 (CH, C-5), 132.8 (Cq, C1), 139.5 (CH, C-2), 166.4 (Cq, COOMe); HREIMS m/z calcd for C8H11O5I [M]+ 313.9652, found 313.9655.

3.2. Synthesis of Pericoxide

Synthesis of Methyl (3R,4R,5R,6S)-5-Bromo-3,4,6-Trihydroxycyclohex-1-ene-1-carBoxylate (11) from 9

A solution of 9 (264 mg, 0.76 mmol) in dry MeOH (4.0 mL) in a microwave (MW) vial was added to Dowex (760 mg). The vial was then sealed and heated under MW irradiation at 100 °C for 30 min. After cooling, the reaction mixture was filtered, the filtrate concentrated under reduced pressure to give the crude product, which was purified via column chromatography (eluent: CH2Cl2:MeOH = 95: 5) to afford 11 (164 mg, 80%). [α]D20 −71.1 (c 1.285, MeOH); IR (liquid film) νmax 3417 (OH), 1714 (C=O), 1650 (C=C) cm−1; 1H-NMR (CD3OD, 600 MHz, ppm) δ 3.78 (3H, s, OMe), 3.84 (1H, dd, J = 8.2, 4.1 Hz, H-4), 4.29 (1H, dd, J = 8.2, 5.3 Hz, H-5), 4.47 (1H, t, J = 4.1 Hz, H-3), 4.64 (1H, d, J = 5.3 Hz, H-6), 6.77 (1H, dd, J = 4.1, 0.6 Hz, H-2); 13C-NMR (CD3OD, 150 MHz, ppm) δ 52.5 (COOMe-C8), 55.1 (CH, C5), 67.0 (CH, C3), 71.4 (CH, C4), 71.5 (CH, C6), 138.6 (CH, C2), 167.8 (COOMe-C7); HREIMS m/z calcd for C8H12O579Br1 [M + H]+ 266.9868 found 266.9865, C8H12O581Br1 [M + H]+ 268.9848 found 268.9850.

3.3. Intramolecular Epoxidation of Bromotriol 11

To a solution of 1,1,1,3,3,3-hexamethyldisilazane (HMDS) (0.22 mL, 1.07 mmol) in THF (5 mL) was added n-BuLi (0.66 mL, 1.06 mmol) at −78 °C to prepare a solution of lithium hexamethyldisilazide (LHMDS). After stirring for 30 min, the LHMDS solution was added dropwise to a solution of 11 (92.7 mg, 0.35 mmol) in THF (5 mL) at −78 °C. After stirring the reaction mixture at −78 °C for 1 h, the resulting mixture was warmed to rt and stirred for another 1 h. The reaction mixture was then treated with sat. NH4Cl aq. (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated to give the crude product, which was purified by column chromatography (CH2Cl2: MeOH = 95: 5) to afford methyl (1S,2S,5R,6R)-2,5-dihydroxy-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylate (12) (27.4 mg, 42%). [α]D20 −27.2 (c 0.29, MeOH); IR (liquid film) νmax 3391 (OH), 1713 (C=O), 1655 (C=C) cm−1; 1H-NMR (CD3OD, 600 MHz, ppm) δ 3.05 (1H, ddd, J = 4.0, 2.6, 0.9, H-6), 3.54 (1H, dd, J = 4.1 2.9 Hz, H-1), 3.76 (3H, s, COOMe), 4.49 (1H, dd, J = 4.4, 2.3 Hz, H-5), 4.58 (1H, s, OH), 4.68 (1H, dd, J = 2.6, 1.2 Hz, H-2), 6.43 (1H, dd, J = 4.1, 2.3 Hz, H-4); 13C-NMR (CD3OD, 150 MHz, ppm) δ 52.4 (CH3, COOMe), 55.4 (CH, C-6), 56.0 (CH, C-1), 64.1 (CH, C-2), 65.9 (CH, C-5), 131.5 (Cq, C-3), 137.8 (CH, C-4),168.0 (Cq, COOMe); HREIMS m/z calcd for C8H11O5 [M + H]+ 187.0606 found 187.0604.

3.4. Synthesis of (−)-Pericoxide (7)

A solution of 1.6 M n-BuLi in hexane (0.17 mL, 0.27 mmol) was added to a solution of HMDS (0.089 mL, 0.43 mmol) in THF (2 mL) at −78 °C with stirring to prepare an LHMDS solution. After 40 min, the prepared LHMDS solution was added to a solution of 10Br (22.1 mg, 0.085 mmol) in THF (2 mL) at −78 °C. After stirring for 1.5 h at −78 °C, the reaction mixture was quenched with sat. NH4Cl aq. (20 mL) and extracted with EtOAc (7 × 20 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure to give the crude product, which was purified via column chromatography (eluent; CH2Cl2:MeOH = 97:3) using neutral silica gel (DIOL MB100–75/200, Fiji Silysia Co.) to afford (+)-1 (11.9 mg, 77%); Colorless oil; [α]D20 −68.3 (c 0.60, MeOH); IR (film) νmax 3414 (OH), 1720 (C=O), 1651 (C=C) cm−1; 1H-NMR (CD3OD, 600 MHz, ppm) δ 3.63 (1H, ddd, J = 4.4, 2.1, 1.5 Hz, H-5), 3.81 (3H, s, COOMe), 3.97 (1H, d, J = 4.1 Hz, H-6), 3.98 (1H, d, J = 4.4 Hz, H-4), 4.21 (1H, ddd, J = 6.2, 5.0, 2.1 Hz, H-3), 4.58 (1H, s, OH), 7.12 (1H, dd, J = 6.5, 2.4 Hz, H-2); 13C-NMR (CD3OD, 150 MHz, ppm) δ 50.1 (CH-C6), 52.8 (COOMe-C8), 58.7 (CH-C5), 66.6 (CH-C3), 68.6 (CH-C4), 132.0 (CH, C-1), 143.3 (CH, C-2), 167.3 (Cq, COOMe); HREIMS m/z calcd for C8H10O5 [M]+ 186.0528, found 186.0523.
(+)-7 (3.7 mg, 87%) was synthesized from (+)-10Br (6.2 mg, 0.023 mmol) in the same manner. Colorless oil; [α]D20 +65.8 (c 0.60, MeOH); 1H-NMR (CD3OD, 600 MHz, ppm) δ 3.63 (1H, ddd, J = 4.4, 2.1, 1.5 Hz, H-5), 3.81 (3H, s, COOMe), 3.96–3.98 (2H, m, H-4, H-6), 4.21 (1H, ddd, J = 6.2, 5.0, 2.1 Hz, H-3), 4.57 (1H, s, OH), 7.12 (1H, dd, J = 6.5, 2.4 Hz, H-2); 13C-NMR (CD3OD, 150 MHz, ppm) δ 50.1 (CH-C6), 52.8 (COOMe-C8), 58.7 (CH-C5), 66.6 (CH-C3), 68.6 (CH-C4), 132.0 (CH, C-1), 143.3 (CH, C-2), 167.2 (Cq, COOMe), *some degradation was detected during measuring the 13C-NMR spectrum; HREIMS m/z calcd for C8H10O5 (M)+ 186.0528, found 186.0525; Literature data of (+)-7 [34]: [α]D +74 (c = 0.13, MeOH); 1H-NMR (CD3OD, 400 MHz, ppm) δ 3.64 (1H, m, H-5), 3.81 (3H, s, COOMe), 3.96 (1H, m, H-6), 3.98 (1H, m, H-4), 4.21 (1H, m, H-3), 4.58 (1H, s, OH), 7.10 (1H, dd, J = 6.4, 2. 3 Hz, H-2); 13C-NMR (CD3OD, 100 MHz, ppm) δ 50.1 (CH, C-6), 52.8 (CH3, COOMe), 58.6 (CH, C-5), 66.4 (CH, C-3), 68.5 (CH, C-4), 131.2 (CH, C-1), 143.2 (CH-2), 167.2 (Cq, C-7); HRESIMS m/z calcd for C8H10O5Na [M + Na]+ 209.0420, found 209.0416.

3.5. Biological Assay

Antitumor and glucosidase inhibitory assays were performed using the same procedures as those described in our previous paper [35].

4. Conclusions

The synthesis of both enantiomers of pericosine A analogs bearing F, Br, and I atoms was achieved for the first time and their antitumor activity against P388, L1210, and HL-60 cell lines was evaluated. Although all of the synthesized compounds were moderately active against the three types of tumor cell lines studied, significant differences between their enantiomers and differences between the halogens, except for fluorine, were not observed. The fluorinated derivatives showed weaker activities than the other analogs and pericosine A.
Form glycosidase inhibitory assay, five synthesized molecules of 1 except for (+)-1F were elucidated to exhibit α-glucosidase inhibitory activity at mM level of IC50. As well, (−)-1Br and (+)-1I showed inhibitory activities against β-galactosidase and α-galactosidase, respectively, at mM level of IC50.
In addition, both enantiomers of pericoxide were synthesized using 6-bromopericosine A as a suitable synthetic precursor.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/md20070438/s1, Figure S1. 1H-NMR spectrum of (−)-10F in CDCl3 (600 MHz), Figure S2. 13C-NMR spectrum of (−)-10F in CDCl3 (150 MHz); Figure S3. 1H-NMR spectrum of (+)-10F in CDCl3 (400 MHz); Figure S4. 13C-NMR spectrum of (+)-10F in CDCl3 (100 MHz); Figure S5. 1H-NMR spectrum of (−)-1F in acetone-d6 (600 MHz); Figure S6. 13C-NMR spectrum of (−)-1F in acetone-d6 (150 MHz); Figure S7. 1H-NMR spectrum of (+)-1F in acetone-d6 (600 MHz); Figure S10. 1H-NMR spectrum of (−)-10Br in CDCl3 (600 MHz); Figure S11. 13C-NMR spectrum of (−)-10Br in acetone-d6 (150 MHz); Figure S12. 1H-NMR spectrum of (+)-10Br in acetone-d6 (600 MHz); Figure S13. 13C-NMR spectrum of (+)-10Br in acetone-d6 (150 MHz); Figure S14. 1H-NMR spectrum of (−)-1Br in methanol-d4 (600 MHz); Figure S15. 13C-NMR spectrum of (−)-1Br in methanol-d4 (150 MHz); Figure S16. 1H-NMR spectrum of (+)-1Br in methanol-d4 (600 MHz); Figure S17. 13C-NMR spectrum of (+)-1Br in methanol-d4 (150 MHz); Figure S18. 1H-NMR spectrum of (−)-10I in CDCl3 (600 MHz); Figure S19. 13C-NMR spectrum of (−)-10I in CDCl3 (150 MHz); Figure S20. 1H-NMR spectrum of (+)-10I in CDCl3 (400 MHz); Figure S21. 13C-NMR spectrum of (+)-10I in CDCl3 (100 MHz); Figure S22. 1H-NMR spectrum of (−)-1I in acetone-d6 (600 MHz); Figure S23. 13C-NMR spectrum of (−)-1I in acetone-d6 (150 MHz); Figure S24. 1H-NMR spectrum of (+)-1I in acetone-d6 (600 MHz); Figure S25. 13C-NMR spectrum of (+)-1I in acetone-d6 (150 MHz); Figure S26. 1H-NMR spectrum of (−)-11 in methanol-d4 (600 MHz); Figure S27. 13C-NMR spectrum of (−)-11 in methanol-d4 (150 MHz); Figure S28. 1H-NMR spectrum of (−)-12 in methanol-d4 (600 MHz); Figure S29. 13C-NMR spectrum of (−)-12 in methanol-d4 (150 MHz); Figure S30. HMBC spectrum of (−)-12 in methanol-d4 (600 MHz); Figure S31. 1H-NMR spectrum of (−)-7 in methanol-d4 (600 MHz); Figure S32. 13C-NMR spectrum of (−)-7 in methanol-d4 (150 MHz); Figure S33. 1H-NMR spectrum of (+)-7 in methanol-d4 (600 MHz); Figure S34. 13C-NMR spectrum of (+)-7 in methanol-d4 (150 MHz Table S1. Deprotection of (−)-10Br with Dowex® 50WX8-H.

Author Contributions

Y.U. conceived and designed the experiments and wrote the manuscript. Y.M. performed the synthesis of the pericosine analogs and glycosidase inhibitory assays. T.Y. performed the antitumor assay. M.I., M.M. and K.M. synthesized pericoxide. H.Y. and S.H. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This study received no external funding.

Data Availability Statement

Not applicable.

Acknowledgments

All experimental works described in this paper were performed at Osaka University of Pharmaceutical Sciences (OUPS) until March 2021. The OUPS was renamed Osaka Medical and Pharmaceutical University (OMPU) in April 2021. The authors thank K. Minoura M. Fujitake and M. Shibano of our University for measurement of the NMR, mass spectra, and useful advice on the antiglucosidase assay, respectively. Y. Nakai, S. Fukuda, R. Yamashita, S. Nakagawa, A. Hirokawa, and R. Wakahara of our laboratory are appreciated for their extensive experimental support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gerry, C.J.; Schreiber, S.L. Chemical probes and drug leads from advances in synthetic planning and methodology. Nat. Rev. Drug Discov. 2018, 17, 333–352. [Google Scholar] [CrossRef] [PubMed]
  2. Campos, K.R.; Coleman, P.J.; Alvarez, J.C.; Dreher, S.D.; Garbaccio, R.M.; Terrett, N.K.; Tillyer, R.D.; Truppo, M.D.; Parmee, E.R. The importance of synthetic chemistry in the pharmaceutical industry. Science 2019, 363, eaat0805. [Google Scholar] [CrossRef] [PubMed]
  3. Lee, K.H. Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J. Nat. Prod. 2010, 73, 500–516. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Szychowski, J.; Truchon, J.F.; Bennani, Y.L. Natural products in medicine: Transformational outcome of synthetic chemistry. J. Med. Chem. 2014, 57, 9292–9308. [Google Scholar] [CrossRef] [PubMed]
  5. Ermert, P. Design, properties and recent application of macrocycles in medicinal chemistry. Chimia 2017, 71, 678–702. [Google Scholar] [CrossRef] [PubMed]
  6. Bauer, A.; Broenstrup, M. Industrial natural product chemistry for drug discovery and development. Nat. Prod. Rep. 2014, 31, 35–60. [Google Scholar] [CrossRef]
  7. Koehn, F.E. Biosynthetic medicinal chemistry of natural product drugs. Med. Chem. Comm. 2012, 3, 854–865. [Google Scholar] [CrossRef]
  8. Ghosh, A.K.; Brindisi, M.; Shahabi, D.; Chapman, M.E.; Mesecar, A.D. Drug development and medicinal chemistry efforts toward SARS-Coronavirus and COVID-19 therapeutics. Chem. Med. Chem. 2020, 15, 907–993. [Google Scholar] [CrossRef]
  9. Lu, W.Y.; Li, H.J.; Li, Q.Y.; Wu, Y.C. Application of marine natural products in drug research. Bioorg. Med. Chem. 2021, 35, 11605. [Google Scholar] [CrossRef]
  10. Villa, F.A.; Gerwick, L. Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders. Immunopharmacol. Immunotoxicol. 2010, 32, 228–237. [Google Scholar] [CrossRef]
  11. Kobayashi, J. Search for new bioactive marine natural products and application to drug development. Chem. Pharm. Bull. 2016, 64, 1079–1083. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Khalifa, S.A.M.; Elias, N.; Farag, M.A.; Chen, L.; Saeed, A.; Hegazy, M.E.F.; Moustafa, M.S.; Abd El-Wahed, A.; Al-Mousawi, S.M.; Musharraf, S.G.; et al. Marine natural products: A source of novel anticancer drugs. Mar. Drugs 2019, 17, 491. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Numata, A.; Iritani, M.; Yamada, T.; Minoura, K.; Matsumura, E.; Yamori, T.; Tsuruo, T. Novel antitumour metabolites produced by a fungal strain from a sea hare. Tetrahedron Lett. 1997, 38, 8215–8218. [Google Scholar] [CrossRef]
  14. Yamada, T.; Iritani, M.; Ohishi, H.; Tanaka, K.; Doi, M.; Minoura, K.; Numata, A. Pericosines, antitumour metabolites from the sea hare-derived fungus Periconia byssoides. Structures and biological activities. Org. Biomol. Chem. 2007, 5, 3979–3986. [Google Scholar] [CrossRef] [PubMed]
  15. Usami, Y. Synthesis of marine-derived carbasugar pericosines. In Studies in Natural Product Chemistry; Atta-ur-Rahman, A.Z., Ed.; Pergamon: Oxford, UK, 2014; Volume 41, pp. 287–319. [Google Scholar]
  16. Arjona, O.; Gomez, A.M.; Lopez, J.C.; Plumet, J. Synthesis, and conformational and biological aspects of carbasugars. Chem. Rev. 2007, 107, 1919–2036. [Google Scholar] [CrossRef]
  17. Lahiri, R.; Ansari, A.A.; Vankar, Y.D. Carbasugars and related molecules as glycosidase inhibitors. Chem. Soc. Rev. 2013, 42, 5102–5118. [Google Scholar] [CrossRef]
  18. Ogawa, S.; Kanto, M.; Suzuki, Y. Development and medical application of unsaturated carbaglycosylamine glycosidase inhibitors. Mini-Rev. Med. Chem. 2007, 7, 679–691. [Google Scholar] [CrossRef]
  19. Donohoe, T.J.; Blades, K.; Helliwell, M.; Warning, M.J.; Newcombe, N.J. The synthesis of (+)-pericosine B. Tetrahedron Lett. 1998, 39, 8755–8758. [Google Scholar] [CrossRef]
  20. Usami, Y.; Takaoka, I.; Ichikawa, H.; Horibe, Y.; Tomiyama, S.; Ohtsuka, M.; Imanishi, Y.; Arimoto, M. First total synthesis of antitumor natural product (+)- and (−)-pericosine A:  Determination of absolute stereostructure. J. Org. Chem. 2007, 72, 6127–6134. [Google Scholar] [CrossRef]
  21. Usami, Y.; Ohsugi, M.; Mizuki, K.; Ichikawa, H.; Arimoto, M. Facile and efficient synthesis of naturally occurring carbasugars (+)-pericosines A and C. Org. Lett. 2009, 11, 2699–2701. [Google Scholar] [CrossRef]
  22. Usami, Y.; Suzuki, K.; Mizuki, K.; Ichikawa, H.; Arimoto, M. Synthesis of (−)-pericosine B, antipode of cytotoxic marine natural product. Org. Biomol. Chem. 2009, 7, 315–318. [Google Scholar] [CrossRef] [PubMed]
  23. Boyd, D.R.; Sharma, N.D.; Acaru, C.A.; Malone, J.F.; O’Dowd, C.R.; Allen, C.C.R.; Stevenson, P.J. Chemoenzymatic synthesis of carbasugars (+)-pericosines A–C from diverse aromatic cis-dihydrodiol precursors. Org. Lett. 2010, 12, 2206–2209. [Google Scholar] [CrossRef] [PubMed]
  24. Tripathi, S.; Shaikh, A.C.; Chen, C. Facile carbohydrate-based stereocontrolled divergent synthesis of (+)-pericosines A and B. Org. Biomol. Chem. 2011, 9, 7306–7308. [Google Scholar] [CrossRef] [PubMed]
  25. Reddy, Y.S.; Kadigachalam, P.; Basak, R.K.; Pal, A.P.J.; Vankar, Y.D. Total synthesis of (+)-pericosine B and (+)-pericosine C and their enantiomers by using the Baylis–Hillman reaction and ring-closing metathesis as key steps. Tetrahedron Lett. 2012, 53, 132–136. [Google Scholar] [CrossRef]
  26. MuniRaju, C.; Rao, J.P.; Rao, B.V. Stereoselective synthesis of (+)-pericosine B and (+)-pericosine C using ring closing metathesis approach. Tetrahedron Asymmetry 2012, 23, 86–93. [Google Scholar] [CrossRef]
  27. Li, L.S.; Hou, D.R. Diastereoselective vinylalumination for the synthesis of pericosine A, B and C. RSC Adv. 2014, 4, 91–97. [Google Scholar] [CrossRef]
  28. Babu, D.C.; Rao, C.B.; Venkastesham, K.; Selvam, J.J.P.; Venkasteswarlu, Y. Toward synthesis of carbasugars (+)-gabosine C, (+)-COTC, (+)-pericosine B, and (+)-pericosine C. Carbohydr. Res. 2014, 388, 130–137. [Google Scholar] [CrossRef] [PubMed]
  29. Mizuki, K.; Iwahashi, K.; Murata, N.; Ikeda, M.; Nakai, N.; Yoneyama, H.; Harusawa, S.; Usami, Y. Synthesis of marine natural product (−)-pericosine E. Org. Lett. 2014, 16, 3760–3763. [Google Scholar] [CrossRef]
  30. Bidus, N.; Banachowicz, P.; Buda, S. Application of a tandem seleno-michael/aldol reaction in the total syntheses of (+)-pericosine B, (+)-pericosine C, (+)-COTC and 7-chloro-analogue of (+)-Gabosine C. Tetrahedron 2020, 76, 131397. [Google Scholar] [CrossRef]
  31. Usami, Y.; Mizuki, K.; Kawahata, R.; Shibano, M.; Sekine, A.; Yoneyama, H.; Harusawa, S. Synthesis of natural O-linked carba-disaccharides, (+)- and (–)-pericosine E, and their analogues as α-glucosidase inhibitors. Mar. Drugs 2017, 15, 22. [Google Scholar] [CrossRef] [Green Version]
  32. Usami, Y.; Higuchi, M.; Mizuki, K.; Yamamoto, M.; Kanki, M.; Nakasone, C.; Sugimoto, Y.; Shibano, M.; Uesawa, Y.; Nagai, J.; et al. Syntheses and glycosidase inhibitory activities, and in silico docking studies of pericosine E analogs methoxy-substituted at C6. Mar. Drugs 2020, 18, 221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Du, L.; Robles, A.J.; King, J.B.; Powell, D.R.; Miller, A.N.; Mooberry, S.L.; Cichewicz, R.H. Crowd sourcing natural products discovery to access uncharted dimensions of fungal metabolite diversity. Angew. Chem. Int. Ed. 2014, 53, 804–809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Du, L.; You, J.; Nicholas, K.M.; Cichewicz, R.H. Chemoreactive natural products that afford resistance against disparate antibiotics and toxins. Angew. Chem. Int. Ed. 2016, 55, 4220–4225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Usami, Y.; Nakamura, K.; Mizobuchi, Y.; Yoneyama, H.; Harusawa, S.; Yamada, T. Enantiomeric composition of natural pericosine A derived from Periconia byssoides and α-glycosidase inhibitory activity of (–)-enantiomer. Chirality 2022, 1–8. [Google Scholar] [CrossRef]
  36. Brown, H.C.; Roy, C.D. Dibromoborane-dimethyl sulfide and monobromoborane–dimethyl-sulfide as superior reagents for the opening of oxiranes to bromohydrins. Molecules 1998, 2, 114–120. [Google Scholar] [CrossRef]
  37. Roy, C.D.; Brown, H.C. Monobromoborane-dimethyl sulfide-a highly promising reagent for the regio- and chemoselective brominative cleavage of terminal epoxides into vicinal bromohydrins. Aust. J. Chem. 2007, 60, 139–145. [Google Scholar] [CrossRef]
  38. Bhatt, M.V.; Babu, J.M. New reagents 3: Alumi.ium iodide—A highly regioselective ether-cleaving reagent with novel cleavage pattern. Tetrahedron Lett. 1984, 25, 3497–3500. [Google Scholar]
  39. Du, L.; Munteanu, C.; King, J.B.; Frantz, D.E.; Cichewicz, R.H. An electrophilic natural product provides a safe and robust odor neutralization approach to counteract malodorous organosulfur metabolites encountered in skunk spray. J. Nat. Prod. 2019, 82, 1989–1999. [Google Scholar] [CrossRef]
  40. Kumar, K.S.A.; Rathee, J.S.; Subramanian, M.; Chattopadhyay, S. Divergent synthesis of 4-epi-fagomine, 3,4-dihydroxypipecolic acid, and a dihydroxyindolizidine and their β-galactosidase inhibitory and immunomodulatory activities. J. Org. Chem. 2013, 78, 7406–7413. [Google Scholar] [CrossRef]
  41. Dada, L.; Manzano, V.E.; Varela, O. Design and synthesis of 2-acetamido-2,3-dideoxythiodisaccharides via diastereoselective conjugate addition to sugar enone O-acetyl oximes. galactosidase inhibition studies. Org. Lett. 2018, 20, 6225–6228. [Google Scholar] [CrossRef]
  42. Front, S.; Gallienne, E.; Charollais-Thoenig, J.; Demotz, S.; Martin, O.R. N-Alkyl-, 1-C-silyl-, and 5-C-Alkyl-1,5-dideoxy-1,5-imino-(L)-ribitols as galactosidase inhibitors. Chem. Med. Chem. 2016, 11, 133–141. [Google Scholar] [CrossRef] [PubMed]
  43. Govindaraj, R.G.; Manavalan, B.; Lee, G.; Choi, S. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in toll-like receptor signaling. PLoS ONE 2010, 5, e12713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Yamamoto, K.; Miyake, H.; Kusunoki, M.; Osaki, S. Crystal structures of isomaltase from Saccharomyces cerevisiae and in complex with its competitive inhibitor maltose. FEBS J. 2010, 277, 4205–4214. [Google Scholar] [CrossRef] [PubMed]
  45. Tang, H.; Zhao, D.; Xue, Z. Exploring the interaction between Salvia miltiorrhiza and α-glucosidase: Insights from computational analysis and experimental studies. RSC Adv. 2018, 8, 24701–24710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Kalinowsky, L.; Weber, J.; Balasupramaniam, S.; Baumann, K.; Proschak, E. A diverse benchmark based on 3D matched molecular pairs for validating scoring functions. ACS Omega 2018, 3, 5704–5714. [Google Scholar] [CrossRef] [PubMed]
  47. Rivera-Chavez, J.; Gonzalez-Andrade, M.; Gonzalez Mdel, C.; Glenn, A.E.; Mata, R. Thielavins A, J and K: α-Glucosidase inhibitors from MEXU 27095, an endophytic fungus from Hintonia latiflora. Phytochemistry 2013, 94, 198–205. [Google Scholar] [CrossRef] [PubMed]
  48. Murugesu, S.; Ibrahim, Z.; Ahmed, Q.U.; Yusoff, N.I.N.; Uzir, B.F.; Perumal, V.; Abas, F.; Saari, K.; El-Seedi, H.; Khatib, A. Characterization of α-glucosidase inhibitors from Clinacanthus nutans lindau leaves by gas chromatography-mass spectrometry-based metabolomics and molecular docking simulation. Molecules 2018, 23, 2402. [Google Scholar] [CrossRef] [Green Version]
  49. Murugesu, S.; Ibrahim, Z.; Ahmed, Q.U.; Uzir, B.F.; Yusoff, N.I.N.; Perumal, V.; Abas, F.; Shaari, K.; Khatib, A. Identification of α-glucosidase inhibitors from Clinacanthus nutans leaf extract using liquid chromatography-mass spectrometry-based metabolomics and protein-ligand interaction with molecular docking. J. Pharm. Anal. 2019, 9, 91–99. [Google Scholar] [CrossRef]
  50. Gopalan, G.; Prabha, B.; Joe, A.; Reshmitha, T.R.; Sherin, D.R.; Abraham, B.; Sabu, M.; Manojkumar, T.K.; Radhakrishnan, K.V.; Nisha, P. Screening of Musa balbisiana Colla. seeds for antidiabetic properties and isolation of apiforol, a potential lead, with antidiabetic activity. J. Sci. Food Agric. 2019, 99, 2521–2529. [Google Scholar] [CrossRef]
Marinedrugs 20 00438 g001 550
Figure 1. Structures of the pericosines and their related natural products.
Figure 1. Structures of the pericosines and their related natural products.
Marinedrugs 20 00438 g001
Marinedrugs 20 00438 sch001 550
Scheme 1. Synthesis of 6-halogenated pericosine A. (a) Synthesis of (-)-1 from (-)-shikimic acid; (b) Synthesis of (+)-1 from (-)-quinic acid.
Scheme 1. Synthesis of 6-halogenated pericosine A. (a) Synthesis of (-)-1 from (-)-shikimic acid; (b) Synthesis of (+)-1 from (-)-quinic acid.
Marinedrugs 20 00438 sch001
Marinedrugs 20 00438 sch002 550
Scheme 2. Synthesis of (−)- and (+)-pericoxide (7): (a) (−)-Pericoxide from (−)-shikimic acid; (b) (+)-pericoxide from (−)-quinic acid.
Scheme 2. Synthesis of (−)- and (+)-pericoxide (7): (a) (−)-Pericoxide from (−)-shikimic acid; (b) (+)-pericoxide from (−)-quinic acid.
Marinedrugs 20 00438 sch002
Table
Table 1. Antitumor activity of the synthetic 6-halo-analogs of pericosine A.
Table 1. Antitumor activity of the synthetic 6-halo-analogs of pericosine A.
IC50 (μM)
CompoundP388L1210HL-60
(+)-Pericosine A (1Cl)355.006.122.03
(−)-Pericosine A (1Cl)354.853.962.33
(+)-6-Fluoropericosine A (1F)9.9144.010.8
(−)-6-Fluoropericosine A (1F)9.0338.09.46
(+)-6-Bromopericosine A (1Br)5.395.665.57
(−)-6-Bromopericosine A (1Br)5.656.306.08
(+)-6-Iodopericosine A (1I)6.178.186.78
(−)-6-Iodopericosine A (1I)5.918.276.45
5-FU (positive control)3.860.630.22
Table
Table 2. Glycosidase inhibitory activity of the synthetic 6-halo-congeners of pericosine A.
Table 2. Glycosidase inhibitory activity of the synthetic 6-halo-congeners of pericosine A.
IC50 (mM)
Compoundα-Glucosidase aβ-Glucosidase bα-Mannosidase cα-Galactosidase dβ-Galactosidase e
(+)-1Cl35NI fNINININI
(−)-1Cl352.25NININI5.38
(+)-1FNININININI
(−)-1F1.95NINININI
(+)-1Br5.05NINININI
(−)-1Br1.79NININI5.60
(+)-1I1.15NINI3.56NI
(−)-1I3.60NINININI
DNJ (positive control)0.09650.195–––
a Yeast, b Sweet almond, c Jack bean, d Green coffee bean, e Bovine liver, f NI: No inhibition (IC50 >9.25 mM).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Usami, Y.; Mizobuchi, Y.; Ijuin, M.; Yamada, T.; Morita, M.; Mizuki, K.; Yoneyama, H.; Harusawa, S. Synthesis of 6-Halo-Substituted Pericosine A and an Evaluation of Their Antitumor and Antiglycosidase Activities. Mar. Drugs 2022, 20, 438. https://doi.org/10.3390/md20070438

AMA Style

Usami Y, Mizobuchi Y, Ijuin M, Yamada T, Morita M, Mizuki K, Yoneyama H, Harusawa S. Synthesis of 6-Halo-Substituted Pericosine A and an Evaluation of Their Antitumor and Antiglycosidase Activities. Marine Drugs. 2022; 20(7):438. https://doi.org/10.3390/md20070438

Chicago/Turabian Style

Usami, Yoshihide, Yoshino Mizobuchi, Mai Ijuin, Takeshi Yamada, Mizuki Morita, Koji Mizuki, Hiroki Yoneyama, and Shinya Harusawa. 2022. "Synthesis of 6-Halo-Substituted Pericosine A and an Evaluation of Their Antitumor and Antiglycosidase Activities" Marine Drugs 20, no. 7: 438. https://doi.org/10.3390/md20070438

APA Style

Usami, Y., Mizobuchi, Y., Ijuin, M., Yamada, T., Morita, M., Mizuki, K., Yoneyama, H., & Harusawa, S. (2022). Synthesis of 6-Halo-Substituted Pericosine A and an Evaluation of Their Antitumor and Antiglycosidase Activities. Marine Drugs, 20(7), 438. https://doi.org/10.3390/md20070438

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop